Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Li Auto Inc (LI) vs Medpace Holdings Inc (MEDP) Price & Performance

Li Auto IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

Li Auto Inc vs Medpace Holdings Inc — how do they compare? Li Auto Inc trades at $12.5 (market cap $12.28B), while Medpace Holdings Inc trades at $601.66 (market cap $16.90B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.

LIMEDP
Market Cap
$12.28B$16.90B
Sector
Consumer CyclicalTechnology
52-Week High
$26.69$620.59
52-Week Low
$11.74$393.42
Enterprise Value
$1.11B$16.52B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Li Auto Inc

Li Auto (LI) trades at $12.505, down 2.61% on the day, with a bearish technical signal and mixed earnings performance. Recent quarterly results show misses on EPS estimates, while revenue declined to $112.31 billion in 2025. The company maintains strong delivery growth, with 30,468 vehicles delivered in July 2026, but faces intense competition in China's EV market. Cash flow trends indicate operational challenges, with negative net cash flow of $9.00 billion in 2025.

Outlook remains cautious due to profitability pressures and competitive headwinds, though analyst consensus suggests moderate upside to a $14.80 price target. Key risks include execution on new model launches and macroeconomic volatility in the EV sector. The stock's current valuation metrics, such as a P/S of 0.83, may appeal to value-oriented investors if operational improvements materialize.

Medpace Holdings Inc

MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.

Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Li Auto Inc

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.

Read more on LI

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP